<DOC>
	<DOCNO>NCT02278887</DOCNO>
	<brief_summary>In randomize controlled phase III study investigator evaluate whether TIL infusion precede non-myeloablative chemotherapy follow high dose bolus interleukin-2 result improve progression free survival randomly compare ipilimumab 168 stage IV melanoma patient . A health technology assessment ( HTA ) perform evaluate impact TIL treatment patient organizational process cost-effectivity .</brief_summary>
	<brief_title>Study Comparing TIL Standard Ipilimumab Patients With Metastatic Melanoma</brief_title>
	<detailed_description>In randomize controlled phase III study investigator evaluate whether TIL infusion precede non-myeloablative chemotherapy follow high dose bolus interleukin-2 result improve progression free survival randomly compare ipilimumab 168 stage IV melanoma patient . A health technology assessment ( HTA ) perform evaluate impact TIL treatment patient organizational process cost-effectivity . This do via questionnaire baseline , treatment follow-up . Also healthcare provider interview 6 month start trial .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm unresectable AJCC stage III stage IV melanoma Patients must metastatic melanoma resectable metastatic lesion ( ) sufficient size ( ≥ 23 cm total ) must willing undergo resection experimental purpose . Patients receive maximum one line systemic therapy ( except ipilimumab ) unresectable metastatic melanoma . [ Patients must ≥ 18 year ≤ 75 year age must measurable disease CT MRI per RECIST 1.1 criterion ( addition resect lesion ) . Patients must clinical performance status ECOG 0 1 . Patients gender must willing practice highly effective method birth control treatment four month receive preparative regimen . Patients must able understand sign Informed Consent document . Life expectancy less three month . Patients metastatic ocular/ mucosal noncutaneous melanoma . Adjuvant treatment ipilimumab within 6 month prior randomization . Requirement immunosuppressive dos systemic corticosteroid ( &gt; 10 mg/day prednisone equivalent ) immunosuppressive drug within last 3 week prior randomization . Patients two CNS metastasis . Patients CNS lesion symptomatic , great 1 cm diameter show significant surround edema MRI scan eligible treat demonstrated clinical radiologic CNS progression least 2 month . All patient ' toxicity due prior nonsystemic treatment must recover grade 1 less . Patients may undergo minor surgical procedure focal palliative radiotherapy ( nontarget lesion ) within past 4 week , long toxicity recover grade 1 less . Women pregnant breastfeeding , potentially dangerous effect preparative chemotherapy fetus infant . Any active systemic infection , coagulation disorder active major medical illness . Any autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>melanoma</keyword>
	<keyword>TIL treatment</keyword>
	<keyword>tumor infiltrate lymphocyte</keyword>
	<keyword>ipilimumab</keyword>
	<keyword>interleukin 2</keyword>
	<keyword>non-myeloablative</keyword>
	<keyword>randomization</keyword>
</DOC>